GlassScriptPhysician profile
Siddharth Jani
NPI 1497757595
$8,641.51
in general payments reported to CMS, 2019-2025
36 companies · $2,637 in 2025
The $2,637 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $357 · 2021: $877 · 2022: $1,289 · 2023: $1,100 · 2024: $1,499 · 2025: $2,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,525 · Travel and Lodging: $1,336 · Education: $225 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,524.95 |
| Travel and Lodging | $1,335.77 |
| Education | $225.18 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,713.89 | 2024-2025 | Inspire |
| Harmony Biosciences LLC | $1,047.80 | 2021-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $967.49 | 2019-2025 | |
| Novo Nordisk INC | $714.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $454.32 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $439.32 | 2019-2025 | |
| Amgen INC. | $376.96 | 2019-2025 | Repatha, Tavneos, Evenity |
| Lilly USA, LLC | $317.22 | 2019-2025 | Zepbound, Mounjaro |
| Avadel Cns Pharmaceuticals, LLC | $281.13 | 2024-2025 | Lumryz |
| Abbvie INC. | $274.40 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $269.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $250.88 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $232.00 | 2022-2025 | |
| Mylan Specialty L.P. | $222.85 | 2019-2024 | Yupelri |
| Axsome Therapeutics, INC. | $215.35 | 2023-2025 | Sunosi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $123.99 | 2021-2023 | Eliquis |
| Nevro Corp. | $100.72 | 2021 | |
| Avanir Pharmaceuticals, INC. | $96.25 | 2019-2022 | |
| Daiichi Sankyo INC. | $84.11 | 2020-2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.61 | 2019-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $65.56 | 2019 | |
| Dexcom, INC. | $37.60 | 2023 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $28.77 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $26.57 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $26.07 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.99 | 2021 | |
| Itamar Medical INC | $23.20 | 2023-2025 | Watchpatone |
| Takeda Pharmaceuticals U.S.A., INC. | $21.98 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.88 | 2022 | |
| Amryt Pharma Holdings LTD | $17.65 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.41 | 2024 | Voquezna |
| Lundbeck LLC | $16.50 | 2024 | Vyepti |
| Scynexis, INC. | $16.02 | 2022 | |
| Astellas Pharma US INC | $13.61 | 2023 | Veozah |
| Kowa Pharmaceuticals America, INC. | $11.58 | 2021 | |
| Allergan, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siddharth Jani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.